Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA55 Injection in Healthy Adults
NCT06050460Phase 1Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SA55 Injection with Placebo (2 arms). Primary endpoint: Incidence of participants with adverse events (AEs) and serious AEs at 6 months. Started Jun 2023; status: recruiting.
02
Drugs
SA55
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06050460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050460.